ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Rezūm water vapor thermal therapy for large-volume, symptomatic benign prostatic enlargement Large, multicenter, real-world cohort with two-year followup.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- Asia-Pacific collaborative consensus statements on water vapor thermal therapy (Rezūm) incorporating a systematic review, a two-round Delphi survey, and a consensus meeting.Prostate international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWater vapor thermal therapy (WVTT), Rezūm, is a minimally invasive therapy that uses water vapor to ablate benign prostatic tissue. This study aimed to present the prospective, multicenter outcomes of the largest cohort of prostates ≥80 mL treated with Rezūm.
methodsThis study involved a prospective, WVTT registry that collated information from two high-volume centers between April 2019 and August 2024. Baseline medical histories, uroflowmetry (peak flow rate [Qmax], postvoid residual [PVR]), and validated questionnaires (International Prostate Symptom Score [IPSS], IPSS quality of life (QoL), Benign Prostatic Hyperplasia Impact Index [BPHII], International Index of Erectile Function [IIEF-15], Male Sexual Health Questionnaire for Ejaculatory Dysfunction [MSHQ-EjD]) were recorded. The main outcomes assessed included symptom scores, functional improvement, and safety at baseline, six, 12, and 24 months.
resultsA total of 259 patients with a prostate volume ≥80 mL were treated with Rezūm. The median prostate volume was 105 mL, with 207 patients (81.2%) exhibiting a median lobe. The IPSS improved from 21.8 at baseline to 5.7 at 24 months. The IPSS QoL score improved from 4.5 at baseline to 1.1 at 24 months. At baseline, the Qmax rate was 8.2 mL/s, increasing to 14.9 mL/s at 24 months. PVR volume decreased from 132.5 mL at baseline to 90 mL at 24 months. The BPHII decreased from 7.5 at baseline to 2.3 at 24 months. There was no significant change in sexual function as measured by IIEF and MSHQ.
conclusionsRezūm therapy is a safe, effective, and minimally invasive option for managing large prostates (≥80 mL), providing significant and sustained improvements in urinary symptoms with minimal impact on sexual function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.